Skip to main navigation
Skip to search
Skip to main content
University of Copenhagen Research Portal Home
Help & FAQ
Dansk
English
Home
Profiles
Research output
Research units
Press/Media
Activities
Prizes
???studenttheses???
Datasets
Search by expertise, name or affiliation
Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists
Rasmus M Christensen,
Christian R Juhl
,
Signe S Torekov
Department of Biomedical Sciences
Torekov Group
Endocrinology and Metabolism
5
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
Glucagon-Like Peptide-1 Receptor
66%
Liraglutide
47%
semaglutide
44%
Risk Assessment
42%
Weight Loss
42%
Obesity
35%
Anti-Obesity Agents
24%
Pharmaceutical Preparations
21%
Life Style
20%
Safety
14%
Comorbidity
13%
Body Weight
12%
Placebos
11%
Marketing
9%
Gastrointestinal Diseases
9%
Half-Life
7%
Homeostasis
6%
Hormones
5%
Diet
5%
Drug Therapy
5%
Therapeutics
2%
Chemical Compounds
Glucagon-Like Peptide-1 Receptor Agonist
100%
Liraglutide
65%
Weight
27%
Drug
26%
Antiobesity
25%
Safety
21%
Gastrointestinal Hormone
14%
Once Daily
14%
Reaction Half Life
8%
Disorder
7%
Energy
3%